#None #Faruqi & Faruqi #securities litigation #Actinium Pharmaceuticals

Actinium Pharmaceuticals Investor Alert

In a significant development for investors in Actinium Pharmaceuticals, Inc. (NYSE: ATNM), recent reports from Faruqi & Faruqi, a prominent national securities law firm, underscore the potential for legal claims related to recent declines in the company's stock. Between October 31, 2022, and August 2, 2024, shareholders who have experienced losses exceeding $75,000 are being urged to seek legal advice and explore their options.

The firm is actively investigating possible claims against Actinium due to allegations that the company, alongside its executives, may have violated federal securities laws. The complaint—which has been filed as part of a federal securities class action—accuses the firm of making misleading statements and failing to disclose critical information regarding the company's trial data and regulatory filings related to its Iomab-B Biologics License Application (BLA).

Understanding the Background

As detailed in the allegations, Actinium's assertions regarding the efficacy of data derived from their Sierra Trial were misleading. There are claims that the company misrepresented the probability of meeting the FDA's acceptance criteria for their treatment, thereby leading investors to overestimate the company's prospects

Key issues highlighted include:
1. The belief that data from the Sierra Trial would not meet FDA guidelines.
2. Additions to the analyses intended to support their BLA filing were unlikely to satisfy necessary FDA standards.
3. A potential refusal from the FDA to review the necessary documentation or approve the application in its current state.
4. Misleading statements about the viability and future of the Iomab-B product.

The implications of these allegations have been severe; as investors were gradually informed of the company’s regulatory failures, the value of Actinium’s stock plunged dramatically. Specifically, on August 5, 2024, the firm revealed that further clinical trials would be necessary before proceeding with their BLA—it resulted in a staggering drop of nearly 60%, sending shares down to $2.48.

Call to Action

Faruqi & Faruqi is encouraging any investors who might qualify as lead plaintiffs in this class action to come forward. The lead plaintiff plays a crucial role in directing the litigation on behalf of the class, ensuring that the collective interests of affected investors are represented.

If you feel you’ve been affected by these developments, or if you possess additional information regarding Actinium's conduct, the firm invites you to reach out. This is crucial for maintaining the integrity of the investigation and potentially influencing the outcome for current and former shareholders.

To get in touch with Faruqi & Faruqi, investors can call partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310). For more information or to learn about your rights, please visit Faruqi & Faruqi.

As with any legal matter, remember that prior results do not guarantee future outcomes, and discussions will be held confidentially. With a proven history of recovering hundreds of millions for investors, the firm stands ready to assist those impacted by the unfortunate turn of events at Actinium Pharmaceuticals.